DNTH

Dianthus Therapeutics, Inc.

HealthcareBiotechnologyUSUSDPeers →

$82.49

LiveJun 18, 2026

Market cap

$3.44B

52w range

16.64 – 96.50

P / E

—

EPS · FY 2025

$-4.20

Volume

2.48M

Revenue · FY 2025

$2.04M

-67.35% YoY

Explain this page

Arphra AIPlain-English read on Dianthus Therapeutics, Inc.’s valuation

Revenue · 5Y

$2.0M-67.3%

FY21FY22FY23FY24FY25

Net income · 5Y

$−162.3M-91.1%

FY21FY22FY23FY24FY25

Margins · FY2025

Gross margin100.0%

Operating margin-8739.3%

Net margin-7973.3%

FCF margin-6349.4%

income_statement_annual

Line item	FY2025	FY2024	FY2023	FY2022	FY2021	YoY
Revenue	2.0M	6.2M	2.8M	6.4M	1.5M	-67.3%
Gross profit	2.0M	6.2M	2.8M	6.4M	1.5M	-67.3%
R&D	145.6M	83.1M	32.8M	29.4M	12.6M	+75.2%
Operating income	−177.9M	−101.9M	−48.2M	−29.7M	−13.1M	-74.7%
Net income	−162.3M	−85.0M	−43.6M	−28.5M	−13.1M	-91.1%
Diluted EPS	-4.20	-2.55	-8.45	-7.60	-3.82	-64.7%
Net margin	-7973.3%	-1362.8%	-1541.2%	-443.8%	-888.1%	—

Pro

Full income statement, balance sheet, and cash-flow history is included with Pro.